Home > Publications database > Advancing preclinical biology for Ewing Sarcoma: an international effort. > print

001     304469
005     20250909114905.0
024 7 _ |a 10.1158/1535-7163.MCT-25-0428
|2 doi
024 7 _ |a pmid:40911901
|2 pmid
024 7 _ |a 1535-7163
|2 ISSN
024 7 _ |a 1538-8514
|2 ISSN
037 _ _ |a DKFZ-2025-01862
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Dela Cruz, Filemon S
|0 0000-0002-8356-5191
|b 0
245 _ _ |a Advancing preclinical biology for Ewing Sarcoma: an international effort.
260 _ _ |a Philadelphia, Pa.
|c 2025
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1757409319_22247
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Ewing sarcoma (EwS) is an aggressive bone and soft tissue cancer affecting adolescents and young adults. In vitro and in vivo models of EwS have been instrumental in advancing our understanding of EwS biology and essential in evaluating potential therapies, particularly for metastatic or relapsed disease where effective treatment options remain limited. Through an international collaborative effort between the Children's Oncology Group (COG) Bone Tumor Committee and the Euro Ewing Consortium (EEC), we review the current landscape of preclinical modeling used in EwS research encompassing both in vitro (cell lines and tumor organoids) and in vivo (mouse and non-mammalian xenografts) model systems. We discuss factors that can influence experimental results, provide testing considerations for both in vitro and in vivo studies, and descriptions of existing preclinical data repositories. We highlight current needs in EwS modeling and the importance of enhanced international cooperative research and patient advocacy efforts which will be critical in expanding our resources of biologically-relevant EwS models to enable translation of preclinical findings into effective therapeutic strategies for EwS patients.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Stewart, Elizabeth A
|0 0000-0001-8005-0427
|b 1
700 1 _ |a Surdez, Didier
|0 0000-0002-7118-7859
|b 2
700 1 _ |a Daley, Jessica D
|0 0000-0001-5133-448X
|b 3
700 1 _ |a Soragni, Alice
|0 0000-0002-6634-2885
|b 4
700 1 _ |a Tomazou, Eleni M
|0 0000-0002-7497-4567
|b 5
700 1 _ |a Alvarez-Perez, Jaime
|0 0009-0007-4897-5121
|b 6
700 1 _ |a Feinberg, Tamar Y
|0 0000-0003-2897-036X
|b 7
700 1 _ |a Amatruda, James F
|0 0000-0002-9901-2137
|b 8
700 1 _ |a Ganapathi, Shireen S
|0 0000-0002-1239-2166
|b 9
700 1 _ |a Ohm, Joyce E
|0 0000-0002-7390-8701
|b 10
700 1 _ |a Heske, Christine M
|0 0000-0003-0956-6249
|b 11
700 1 _ |a Cohen-Gogo, Sarah
|0 0000-0002-8852-1104
|b 12
700 1 _ |a Pesic, Dusan
|0 0009-0007-4201-0257
|b 13
700 1 _ |a Nash, Joshua O
|0 0009-0003-2718-2262
|b 14
700 1 _ |a Shlien, Adam
|0 0000-0002-0368-5370
|b 15
700 1 _ |a Roundhill, Elizabeth A
|0 0000-0002-0508-3648
|b 16
700 1 _ |a Burchill, Susan A
|0 0000-0002-1034-3723
|b 17
700 1 _ |a Crompton, Brian D
|0 0000-0001-9404-6621
|b 18
700 1 _ |a Lawlor, Elizabeth R
|0 0000-0002-2350-1540
|b 19
700 1 _ |a Loeb, David M
|0 0000-0002-7319-5000
|b 20
700 1 _ |a Delattre, Olivier
|0 0000-0002-8730-2276
|b 21
700 1 _ |a Mora, Jaume
|0 0000-0002-9386-5980
|b 22
700 1 _ |a Scotlandi, Katia
|0 0000-0001-6114-9499
|b 23
700 1 _ |a Reed, Damon R
|0 0000-0002-8238-2465
|b 24
700 1 _ |a Grohar, Patrick J
|0 0000-0002-1071-4563
|b 25
700 1 _ |a Grünewald, Thomas
|0 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
|b 26
|u dkfz
700 1 _ |a Kovar, Heinrich
|0 0000-0001-6873-9109
|b 27
700 1 _ |a Bailey, Kelly M
|0 0000-0003-3925-3243
|b 28
773 _ _ |a 10.1158/1535-7163.MCT-25-0428
|0 PERI:(DE-600)2062135-8
|p nn
|t Molecular cancer therapeutics
|v nn
|y 2025
|x 1535-7163
909 C O |o oai:inrepo02.dkfz.de:304469
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL CANCER THER : 2022
|d 2024-12-19
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOL CANCER THER : 2022
|d 2024-12-19
920 1 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B410-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21